Cantor Fitzgerald set a $105.00 price objective on Spark Therapeutics (NASDAQ:ONCE) in a research note issued to investors on Wednesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
“This morning, Spark announced initial plans on U.S. pricing, including a wholesale acquisition cost for LUXTURNA of $425,000/eye ($850,000/ patient).”,” Cantor Fitzgerald’s analyst commented.
ONCE has been the topic of a number of other research reports. Cowen reissued a buy rating and set a $95.00 target price on shares of Spark Therapeutics in a report on Tuesday, October 10th. Raymond James Financial restated a buy rating and set a $75.00 price target on shares of Spark Therapeutics in a research report on Thursday, December 7th. Barclays boosted their price target on shares of Spark Therapeutics from $104.00 to $107.00 and gave the company an overweight rating in a research report on Friday, October 13th. Chardan Capital restated a buy rating and set a $100.00 price target on shares of Spark Therapeutics in a research report on Friday, October 13th. Finally, BMO Capital Markets set a $73.00 price target on shares of Spark Therapeutics and gave the company a buy rating in a research report on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $76.03.
Shares of Spark Therapeutics (ONCE) traded down $3.92 during mid-day trading on Wednesday, reaching $51.84. 1,785,400 shares of the company’s stock were exchanged, compared to its average volume of 1,199,500. Spark Therapeutics has a 1-year low of $41.06 and a 1-year high of $91.75. The company has a market cap of $1,870.00 and a PE ratio of -7.20.
Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The business had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.40 million. During the same period in the previous year, the firm earned ($1.07) EPS. The company’s revenue was up 45.8% compared to the same quarter last year. research analysts expect that Spark Therapeutics will post -7.58 earnings per share for the current fiscal year.
In related news, insider Daniel Faga sold 6,000 shares of the company’s stock in a transaction on Friday, October 20th. The shares were sold at an average price of $79.95, for a total value of $479,700.00. Following the completion of the transaction, the insider now directly owns 6,000 shares in the company, valued at $479,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Stephen W. Webster sold 10,000 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $70.14, for a total transaction of $701,400.00. Following the completion of the transaction, the chief financial officer now owns 12,500 shares of the company’s stock, valued at $876,750. The disclosure for this sale can be found here. Insiders sold 62,309 shares of company stock valued at $4,621,085 over the last quarter. 7.30% of the stock is owned by company insiders.
A number of large investors have recently made changes to their positions in ONCE. Ameritas Investment Partners Inc. grew its position in Spark Therapeutics by 23.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 389 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Spark Therapeutics in the second quarter worth $143,000. BNP Paribas Arbitrage SA grew its position in Spark Therapeutics by 530.1% in the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after acquiring an additional 2,449 shares in the last quarter. Pacad Investment Ltd. grew its position in Spark Therapeutics by 75.0% in the second quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in Spark Therapeutics in the third quarter worth $225,000. Institutional investors own 94.91% of the company’s stock.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.